← Back to Patent Explorer
US4542016A Expired / Lapsed US ⏱️ 0.0 years remaining

Non-a non-b hepatitis surface antigen useful for the preparation of vaccines and methods of use

Assignee: Institut Merieux SA
•
Filing: 1981-03-27
•
Granted: 1985-09-17
•
Expires: 2001-03-27
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A new vaccine against viral NANB hepatitis containing NANBs antigen in a physiologically acceptable medium. The vaccine is prepared by selecting serums or plasmas in which the presence of NANBs antigens has been identified and thereafter purifying the said antigens. Antibodies are also set forth.

Inventors

  • 👤 Christian Trepo

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-31 15:31
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/005; A; A61; A61K; A61K39/00; A61K39/12; A61K39/29; C07K16/00; C07K16/08; A61K2039/51; A61K2039/525; A61K2039/5252; A61K38/00; C12; C12N; C12N2770/00; C12N2770/00011; C12N2770/24011; C12N2770/24211; C12N2770/24222; C12N2770/24234

Claims Analysis

Total Claims: 12
Claim 1
Independent Claim 226 words
A vaccine against viral NANB hepatitis comprising in a physiologically acceptable medium an amount of a purified non infectious fraction containing NANBs antigen in quantities sufficient to cause, on administration, an immunologic response, said NANBs antigen (1) having a density between 1.20 and 1.30 g/ml in a cesium chloride solution and between 1.15 and 1.25 g/ml in a sucrose solution (2) having an electrophoretic migration in the α, β-globulin zone; (3) being associated to particles with a viral appearance, spheres or filaments, the most typical of which have a size ranging from 10 to 45 nm in diameter, the complete virion appearing as a double envelope sphere of 35 to 45 nm;(4) when administered to a being having an immune system, said NANBs antigen causes the formation of antibodies with which it provides a precipitation reaction, the said antibodies also being capable of aggregating and/or precipitating the said viral particles including the complete double envelope virions containing a nucleocapside having a size of about 35-45nm, the said antibodies also being capable, when combined with a fluorescence agent, of causing a cytoplasmic and/or membranous fluorescence in liver tissue sections from subjects suffering from NANB hepatitis; the said antibodies being neither capable of aggregating the complete B hepatitis virus particles nor of causing a cytoplasmic and/or membranous fluorescence in the liver tissue of subjects suffering from B hepatitis.
Claim 2
Dependent Claim 226 words
A vaccine against viral NANB hepatitis comprising in a physiologically acceptable medium an amount of a purified non infectious fraction containing NANBs antigen in quantities sufficient to cause, on administration, an immunologic response, said NANBs antigen (1) having a density between 1.20 and 1.30 g/ml in a cesium chloride solution and between 1.15 and 1.25 g/ml in a sucrose solution (2) having an electrophoretic migration in the α, β-globulin zone; (3) being associated to particles with a viral appearance, spheres or filaments, the most typical of which have a size ranging from 10 to 45 nm in diameter, the complete virion appearing as a double envelope sphere of 35 to 45 nm;(4) when administered to a being having an immune system, said NANBs antigen causes the formation of antibodies with which it provides a precipitation reaction, the said antibodies also being capable of aggregating and/or precipitating the said viral particles including the complete double envelope virions containing a nucleocapside having a size of about 35-45nm, the said antibodies also being capable, when combined with a fluorescence agent, of causing a cytoplasmic and/or membranous fluorescence in liver tissue sections from subjects suffering from NANB hepatitis; the said antibodies being neither capable of aggregating the complete B hepatitis virus particles nor of causing a cytoplasmic and/or membranous fluorescence in the liver tissue of subjects suffering from B hepatitis.
Claim 3
Dependent Claim 50 words
A process for preparing the vaccine of claim 1 comprising subjecting a serum or plasma containing NANBs antigen to a method selected from affinity chromatography, ultracentrifugation, gel chromatography, fractioned precipitation or ultrafiltration so as to provide purified NANBs antigen, and dissolving said purified NANBs antigen in a physiologically acceptable medium.
Claim 4
Dependent Claim 30 words
The process of claim 2 wherein said NANBs antigen is present in said serum or plasma in the form of an immunocompound and wherein said process includes dissociating said immunocompound.
Claim 5
Dependent Claim 131 words
A medicine for the prevention and treatment of viral NANB hepatitis comprising in a physiologically acceptable medium a purified gammaglobulin fraction containing anti-NANBs antibodies, the said anti-NANBs antibodies exhibiting principally the following characteristics: (1) they provide a precipitation reaction with NANBs antigens; (2) they are capable of aggregating and/or precipitating viral particles including complete double enveloped virions having a size of 35-45nm, associated to the NANBs antigen; (3) they are capable of causing, when combined with a fluorescence agent, a cytoplasmic and/or membranous fluorescence in liver tissue sections of subjects suffering from NANB hepatitis; and (4) the said antibodies are neither capable of aggregating or precipitating significantly complete particles of the B hepatitis virus nor of causing a cytoplasmic and/or membranous fluorescence in liver tissue of subjects suffering from B hepatitis.
Claim 6
Dependent Claim 131 words
A medicine for the prevention and treatment of viral NANB hepatitis comprising in a physiologically acceptable medium a purified gammaglobulin fraction containing anti-NANBs antibodies, the said anti-NANBs antibodies exhibiting principally the following characteristics: (1) they provide a precipitation reaction with NANBs antigens; (2) they are capable of aggregating and/or precipitating viral particles including complete double enveloped virions having a size of 35-45nm, associated to the NANBs antigen; (3) they are capable of causing, when combined with a fluorescence agent, a cytoplasmic and/or membranous fluorescence in liver tissue sections of subjects suffering from NANB hepatitis; and (4) the said antibodies are neither capable of aggregating or precipitating significantly complete particles of the B hepatitis virus nor of causing a cytoplasmic and/or membranous fluorescence in liver tissue of subjects suffering from B hepatitis.
Claim 7
Dependent Claim 23 words
The medicine of claim 4 wherein said gammaglobulin fraction containing said anti-NANBs antibodies has been previously treated to suppress or reduce anti-complement force.
Claim 8
Dependent Claim 26 words
A process for preventing or treating NANB virus hepatitis and chronic infections comprising administering, intramuscularly or intravenously, a sufficient amount of the medicine of claim 4.
Claim 9
Dependent Claim 34 words
A process for eliminating or reducing the infectiousness of biologic fluids containing or susceptible of containing NANB hepatitis virus or NANBs antigens, comprising contacting said fluids with a gammaglobulin fraction defined in claim 4.
Claim 10
Dependent Claim 41 words
A process for preparing the medicine of claim 1 comprising isolating from a serum or plasma containing anti-NANBs antibodies a purified gammaglobulin fraction free from all other normal or infectious blood protein components, said purified gammaglobulin fraction containing said anit-NANBs antibodies.
Claim 11
Dependent Claim 32 words
A vaccination process against NANB hepatitis comprising administering to an animal having an immune system a purified NANBs antigen preparation containing said antigen in an amount sufficient to cause an immunologic response.
Claim 12
Dependent Claim 32 words
A vaccination process against NANB hepatitis comprising administering to an animal having an immune system a purified NANBs antigen preparation containing said antigen in an amount sufficient to cause an immunologic response.

References Cited (Backward Citations)

US4291020A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1988-09-16 1989-03-18 1989-09-17 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1992-09-16 1993-03-18 1993-09-17 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1996-09-16 1997-03-18 1997-09-17 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag